ValueScreener

ValueScreener company report

IQVIA Holdings Inc. (IQV)

NYSE / Healthcare / Medical - Diagnostics & Research

Share price

271.04 USD Market dataClose of Oct 15, 2026

Market capitalisation

44.61B USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Feb 17, 2026
Ratios computed
Oct 15, 2026
Filed years
10, FY2016 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

8.8% Computed

From the FY2025 filing

Read quality

Valuation

Price to earnings

34.27x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

4.4% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, as filed

FY2016 Revenue: 6.88B USDFY2016 Net income: 72.0M USDFY2017 Revenue: 9.74B USDFY2017 Net income: 1.28B USDFY2018 Revenue: 10.41B USDFY2018 Net income: 259.0M USDFY2019 Revenue: 11.09B USDFY2019 Net income: 191.0M USDFY2020 Revenue: 11.36B USDFY2020 Net income: 279.0M USDFY2021 Revenue: 13.87B USDFY2021 Net income: 966.0M USDFY2022 Revenue: 14.41B USDFY2022 Net income: 1.09B USDFY2023 Revenue: 14.98B USDFY2023 Net income: 1.36B USDFY2024 Revenue: 15.40B USDFY2024 Net income: 1.37B USDFY2025 Revenue: 16.31B USDFY2025 Net income: 1.36B USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
1 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it cheap

Price to earnings is 34.27x at the close of 2026-10-15 on FY2025 figures; the lines are 15.00x (Graham's defensive ceiling) and, by market convention, 10.00x, 25.00x and 40.00x, and this sits between 25.00x and 40.00x.

Today, against the Healthcare sector (223 companies), 34.27x sits at the 66th percentile; the middle half of that group runs from 13.52x to 42.98x.

Is it good

Return on invested capital was 8.8% in FY2025, in the band labelled "Around the cost of capital" (8.0% to 12.0%), on lines anchored on Damodaran's cost-of-capital data.

Today, against the Healthcare sector (233 companies), 8.8% sits at the 63rd percentile; the middle half of that group runs from -37.4% to 12.8%.

Is it safe

Interest coverage was 2.99x in FY2025, in the band labelled "Speculative grade" (1.50x to 3.00x), on lines anchored on Damodaran's interest-coverage table.

Year by year against peers
Whether IQVIA Holdings Inc.'s return on invested capital stayed above the median of the Healthcare sector, year by year. (FY2020 to FY2025, 6 fiscal years of IQVIA Holdings Inc. with a comparable figure)
The direction
Which way IQVIA Holdings Inc.'s return on equity has moved, and how steadily. (FY2016 to FY2025, 10 filed years of IQVIA Holdings Inc.)
What could explain it
What in IQVIA Holdings Inc.'s filed statements could explain the movements. (10 readings drawn from the statement lines IQVIA Holdings Inc. filed)
What to check next
What to check next on IQVIA Holdings Inc., and where in its filings. (6 questions for IQVIA Holdings Inc.)
In one paragraph
One paragraph on IQVIA Holdings Inc.'s returns, cash, balance sheet and price. (14 of sixteen figures read for IQVIA Holdings Inc.)

These are IQV’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research IQVPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Feb 17, 2026, accession 0001628280-26-008322.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

IQVIA Holdings Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax8.8% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Return on equity20.9% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Return on capital employed, pre-tax10.1% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Return on assets4.5% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Gross margin
Why n/a

Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.

n/a ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Operating margin13.4% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Net margin8.3% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
IQV 8.3%
DGX 9.0%LH 6.3%MEDP 17.8%MTD 21.6%DHR 14.7%
6.3%21.6%
Net margin: IQV against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

IQVIA Holdings Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity2.50 ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Current ratio0.75 ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Quick ratio0.75 ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Interest coverage2.99x ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Altman Z-score2.26 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Net debt14.12B ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Total assets 29.94BTotal liabilities 23.31BShareholders' equity 6.50BOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What IQVIA Holdings Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Feb 17, 2026, 0001628280-26-008322).

IQVIA Holdings Inc: balance sheet position
Total assets29.94B FiledFY2025 10-K, filed Feb 17, 2026
Total liabilities23.31B FiledFY2025 10-K, filed Feb 17, 2026
Shareholders' equity6.50B FiledFY2025 10-K, filed Feb 17, 2026
Cash2.14B FiledFY2025 10-K, filed Feb 17, 2026
Total debt16.26B FiledFY2025 10-K, filed Feb 17, 2026
Net debt14.12B
Current ratio0.75
Debt to equity2.50

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

IQVIA Holdings Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings34.27x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
P/E on trailing twelve months32.55x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book7.23x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Price to sales2.88x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Enterprise value to EBIT28.10x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Enterprise value to EBITDA18.43x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Price to earnings over growth0.85 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Diluted earnings per share7.84 USD FiledFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Graham number81.67 USD ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322

We publish no fair value or price target of our own. Value IQV on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for IQVIA Holdings Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

IQVIA Holdings Inc: valuation
Share price271.04 USD
Market capitalisation44.61B USD
Enterprise value to EBITDA18.43x
Graham number81.67 USD
Diluted earnings per share, FY20257.84 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Aug 4, 2017: low 16.52x, median 36.38x, high 258.96x, latest 32.55x. 2,311 trading days with a meaningful ratio. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like IQVIA Holdings Inc

  1. Quest Diagnostics Incorporated (DGX)Market cap 26.38B USD
  2. Labcorp Holdings Inc. (LH)Market cap 26.36B USD
  3. Medpace Holdings, Inc. (MEDP)Market cap 17.55B USD
  4. Mettler-Toledo International Inc. (MTD)Market cap 32.84B USD
  5. Danaher Corporation (DHR)Market cap 162.70B USD

Same industry (Medical - Diagnostics & Research) and size band (Large, 10B to 200B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

IQVIA Holdings Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield4.4% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Free cash flow2.05B USD ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Free cash flow margin12.6% ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
FY2016 Free cash flow: 696.0M USDFY2016 Net income: 72.0M USDFY2017 Free cash flow: 601.0M USDFY2017 Net income: 1.28B USDFY2018 Free cash flow: 795.0M USDFY2018 Net income: 259.0M USDFY2019 Free cash flow: 835.0M USDFY2019 Net income: 191.0M USDFY2020 Free cash flow: 1.34B USDFY2020 Net income: 279.0M USDFY2021 Free cash flow: 2.30B USDFY2021 Net income: 966.0M USDFY2022 Free cash flow: 1.59B USDFY2022 Net income: 1.09B USDFY2023 Free cash flow: 1.50B USDFY2023 Net income: 1.36B USDFY2024 Free cash flow: 2.11B USDFY2024 Net income: 1.37B USDFY2025 Free cash flow: 2.05B USDFY2025 Net income: 1.36B USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

IQVIA Holdings Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
34.27xFY2025Oct 15, 2026
7.23xFY2025Oct 15, 2026
28.10xFY2025Oct 15, 2026
4.4%FY2025Oct 15, 2026
8.8%FY2025Feb 17, 2026
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
2.50FY2025Feb 17, 2026
0.75FY2025Feb 17, 2026
2.88xFY2025Oct 15, 2026
0.85FY2025Oct 15, 2026
2.26FY2025Oct 15, 2026
-2.79FY2025Feb 17, 2026
5/9FY2025Feb 17, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 10 filed fiscal years on record, FY2016 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports IQVIA Holdings Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

IQVIA Holdings Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY202516.31B2.18B1.36B7.842.05B13.4%20.9%10-K, Feb 17, 20260001628280-26-008322
FY202415.40B2.20B1.37B7.492.11B14.3%22.6%10-K, Feb 13, 20250001478242-25-000045
FY202314.98B1.98B1.36B7.291.50B13.2%22.2%10-K, Feb 15, 20240001478242-24-000038
FY202214.41B1.80B1.09B5.721.59B12.5%18.9%10-K, Feb 15, 20230001478242-23-000044
FY202113.87B1.39B966.0M4.952.30B10.0%16.0%10-K, Feb 16, 20220001478242-22-000041
FY202011.36B731.0M279.0M1.431.34B6.4%4.7%10-K, Feb 12, 20210001478242-21-000020
FY201911.09B777.0M191.0M0.96835.0M7.0%3.2%10-K, Feb 18, 20200001564590-20-004901
FY201810.41B741.0M259.0M1.24795.0M7.1%3.9%10-K, Feb 19, 20190001564590-19-003180
FY20179.74B665.0M1.28B5.74601.0M6.8%16.0%10-K, Feb 16, 20180001564590-18-002340
FY20166.88B576.0M72.0M0.47696.0M8.4%0.8%10-K, Feb 16, 20170001193125-17-046709
  • Revenue, compound annual growth FY2016 to FY2025: 10.1%
  • Earnings, compound annual growth FY2016 to FY2025: 38.6%
  • Earnings per share, compound annual growth FY2016 to FY2025: 36.7%
  • Free cash flow, compound annual growth FY2016 to FY2025: 12.8%

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

IQVIA Holdings Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-2.79 ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Piotroski F-score5/9 ComputedFY2025 10-K, filed Feb 17, 2026, 0001628280-26-008322
Named tests met1 of 30 Computed
Beta0.91 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 1 met, 27 not met, 2 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
ROIC at or above WACC
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff)
Not measured
Dividends and buybacks; Cash-covered dividend. A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(6)
  • Gross Margin: Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.
  • Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 6 figures could not be read on this company, among them Gross Margin, Dividend Yield, Payout Ratio. Each blank in the table above names the rest, with its reason. 2 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map
  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.